Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1
NCT05983432
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
- NCT05983432 ↗
- Recruiting
- SystImmune Inc.
- Focused
We haven't built an HCP commentary report on NCT05983432 (BL-B01D1 in Non Small Cell Lung Cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT05983432 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 4 |
The trial
ClinicalTrials.gov- Official title
- A Phase 1 Study Evaluating the Safety, Tolerability, and Efficacy of BL-B01D1 in Subjects With Metastatic or Unresectable Non-Small Cell Lung Cancer and Other Solid Tumors
- Phase
- Phase 1
- Status
- Recruiting
- Conditions
- Non Small Cell Lung Cancer; Esophageal Cancer; Small Cell Lung Cancer; Nasopharyngeal Cancer; Head and Neck Squamous Cell Carcinoma; Prostate Adenocarcinoma; Ovarian Cancer; Endometrial Cancer; Cervical Cancer; Triple Negative Breast Cancer
- Interventions
- BL-B01D1
- Arms
- BL-B01D1 administered Day 1 and Day 8 per cycle · Experimental
- BL-B01D1 administered Day 1 per cycle · Experimental
- Enrollment
- 540 (estimated)
- Primary outcomes
- Participants with Dose-limiting toxicities
- Participants with Serious Adverse Events (SAEs) and treatment-emergent adverse events (TEAEs),
- Participants with abnormal physical examination findings
- Participants with ability to care for themselves, daily activity, and physical activity
- Participants with abnormal ECG reading
- Participants with abnormal lab results
- To determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and two or more recommended doses and schedules for recommended dose expansion (RDEs) of BL-B01D1 in metastatic NSCLC
- Sponsor
- SystImmune Inc.
- Start
- Aug 8, 2023
- Primary completion
- Apr 20, 2030 (estimated)
- Results posted
- No
- Registry record
- NCT05983432 · updated Sep 21, 2026